Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teduglutide - Takeda

Drug Profile

Teduglutide - Takeda

Alternative Names: ALX-0600; Gattex; Revestive; Teduglutide - Shire

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toronto General Hospital; University of Toronto
  • Developer Shire; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease

Highest Development Phases

  • Marketed Short bowel syndrome
  • Suspended Crohn's disease
  • No development reported Mucositis

Most Recent Events

  • 05 Aug 2019 Shire completes a phase III trial for Short Bowel Syndrome (In adolescents, In adults, In the elderly) in Japan (SC) (NCT03663582)
  • 01 Aug 2019 Teduglutide - Takeda receives Orphan Drug status for Short bowel syndrome (In children) in Japan before August 2019 (Takeda pipeline, August 2019)
  • 18 May 2019 Launched for Short bowel syndrome (In adolescents, In children, In infants) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top